EGLN1 and osteoporosis: Moreover, mice lacking PHD2 in osteocytes are protected from disuse- and oestrogen deficiency-induced bone loss, suggesting that therapeutic targeting of PHD2 can potentially be used for the treatment of osteoporosis.